Kathryn M. Thrailkill, MD

Practice areas

  • Pediatric Endocrinology

Practice areas

  • Pediatric Endocrinology

Clinical interests

  • Pediatric Endocrinology

Kathryn M. Thrailkill, MD

Biography

My name is Kathryn M. Thrailkill, I received my medical degree from The Ohio State University, College of Medicine, Columbus. I completed a residency and fellowship in Pediatric Endocrinology at Duke University Medical Center, Durham, N.C.

I am board certified by the American Board of Pediatrics in General Pediatrics and Endocrinology.

Faculty rank

Professor of Pediatrics

Education

Degree
The Ohio State University, College of Medicine, Columbus

Residency
Duke University Medical Center, Durham, N.C.

Fellowship
Pediatric Endocrinology, Duke University Medical Center, Durham, N.C.

Certifications or Special training
American Board of Pediatrics
American Board of Pediatrics, Endocrinology

Pediatric Endocrinology

Pediatric Specialty Clinic

Kentucky Clinic
Second Floor, Wing D, Room J201
740 S. Limestone
Lexington KY 40536-0284

HBCicon120x123
This is a clinic of the University of Kentucky Hospital, also known as UK Albert B. Chandler Hospital. Read more »

Call 859-323-6211
Call 859-323-5404
Fax 859-323-8179

Amenities
Dining, Internet/Wi-Fi, Information desk, Pharmacy services, Wheelchairs

Parking is available at the Kentucky Clinic Parking Garage (PS #3).

Kentucky Clinic Map (PDF, 616 KB) »
Kentucky Clinic parking information »


Insurance information

Insurance policies can vary widely. Please check with your doctor/clinic for specific insurance information before your visit or procedure to avoid unexpected out-of-pocket costs. See list of insurers »

Referral form for physicians »

 
  1. Thrailkill KM, Clay Bunn R, Nyman JS, Rettiganti MR, Cockrell GE, Wahl EC, Uppuganti S, Lumpkin CK, Fowlkes JL.
    SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.
    Bone. 2016 Jan;82:101-7.
  2. Thrailkill KM, Fowlkes JL, Hyde JF, Litton JC.
    The effects of co-therapy with recombinant human insulin-like growth factor I and insulin on serum leptin levels in adolescents with type 1 diabetes mellitus.
    Pediatr Diabetes. 2001 Mar;2(1):25-9.
  3. Thrailkill KM.
    Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility.
    Diabetes Technol Ther. 2000;2(1):69-80.
  4. Fowlkes JL, Serra DM, Nagase H, Thrailkill KM.
    MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth.
    Ann N Y Acad Sci. 1999 Jun 30;878:696-9.